Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 25
1979 37
1980 35
1981 27
1982 28
1983 54
1984 38
1985 45
1986 63
1987 73
1988 44
1989 73
1990 84
1991 79
1992 110
1993 103
1994 121
1995 108
1996 124
1997 119
1998 139
1999 102
2000 113
2001 78
2002 85
2003 93
2004 78
2005 86
2006 98
2007 77
2008 59
2009 52
2010 61
2011 54
2012 59
2013 57
2014 41
2015 54
2016 60
2017 60
2018 55
2019 38
2020 39
2021 42
2022 50
2023 45
2024 31
2025 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,067 results

Results by year

Filters applied: . Clear all
Page 1
Selegiline: a molecule with innovative potential.
Tábi T, Vécsei L, Youdim MB, Riederer P, Szökő É. Tábi T, et al. J Neural Transm (Vienna). 2020 May;127(5):831-842. doi: 10.1007/s00702-019-02082-0. Epub 2019 Sep 27. J Neural Transm (Vienna). 2020. PMID: 31562557 Free PMC article. Review.
The first was the elucidation of the novel pharmacological properties of selegiline as a selective MAO-B inhibitor by Knoll and Magyar and the original idea of Riederer and Youdim, supported by Birkmayer, to explore its effect in parkinsonian patients with on-off phases. . …
The first was the elucidation of the novel pharmacological properties of selegiline as a selective MAO-B inhibitor by Knoll and Magya …
Selegiline-transdermal--Somerset: Emsam.
[No authors listed] [No authors listed] Drugs R D. 2003;4(1):59-60. doi: 10.2165/00126839-200304010-00012. Drugs R D. 2003. PMID: 12568641 Review. No abstract available.
Transdermal selegiline.
Patkar AA, Pae CU, Zarzar M. Patkar AA, et al. Drugs Today (Barc). 2007 Jun;43(6):361-77. doi: 10.1358/dot.2006.43.6.1050794. Drugs Today (Barc). 2007. PMID: 17612708 Review.
Efforts to address these safety issues led to the development of a transdermal formulation of selegiline, called selegiline transdermal system (STS). STS has been approved by the U.S. ...Compared to oral administration, transdermal selegiline leads to sustain …
Efforts to address these safety issues led to the development of a transdermal formulation of selegiline, called selegiline tr …
The pharmacology of selegiline.
Magyar K. Magyar K. Int Rev Neurobiol. 2011;100:65-84. doi: 10.1016/B978-0-12-386467-3.00004-2. Int Rev Neurobiol. 2011. PMID: 21971003 Review.
The metabolites are also taking part in the complex pharmacological activity of selegiline. The simultaneous presence of the pro- and antiapoptotic effects of selegiline and its metabolites frequently hindered its clinical usage. ...Selegiline is administered …
The metabolites are also taking part in the complex pharmacological activity of selegiline. The simultaneous presence of the pro- and …
Classics in Chemical Neuroscience: Selegiline, Isocarboxazid, Phenelzine, and Tranylcypromine.
Hoffman GR, Olson MG, Schoffstall AM, Estévez RF, Van den Eynde V, Gillman PK, Stabio ME. Hoffman GR, et al. ACS Chem Neurosci. 2023 Dec 6;14(23):4064-4075. doi: 10.1021/acschemneuro.3c00591. Epub 2023 Nov 15. ACS Chem Neurosci. 2023. PMID: 37966854 Review.
It is therefore timely to review key aspects of the four "classic" MAOIs: high-dose selegiline, isocarboxazid, phenelzine, and tranylcypromine. This review discusses their chemical synthesis, metabolism, pharmacology, adverse effects, and the history and importance of thes …
It is therefore timely to review key aspects of the four "classic" MAOIs: high-dose selegiline, isocarboxazid, phenelzine, and tranyl …
Metabolism of selegiline [(-)-deprenyl)].
Kalász H, Magyar K, Szőke É, Adeghate E, Adem A, Hasan MY, Nurulain SM, Tekes K. Kalász H, et al. Curr Med Chem. 2014;21(13):1522-30. doi: 10.2174/0929867321666131218094352. Curr Med Chem. 2014. PMID: 24350849 Review.
In addition, more than 40 minor metabolites of selegiline (1) have also been either detected or proposed by investigators and researchers. This review analyses the pharmacological activity, generation pathway and the detection method of the major metabolites of selegili …
In addition, more than 40 minor metabolites of selegiline (1) have also been either detected or proposed by investigators and researc …
Pharmacology of selegiline.
Gerlach M, Youdim MB, Riederer P. Gerlach M, et al. Neurology. 1996 Dec;47(6 Suppl 3):S137-45. doi: 10.1212/wnl.47.6_suppl_3.137s. Neurology. 1996. PMID: 8959982 Review.
Selegiline is readily absorbed from the gastrointestinal tract and rapidly enters the brain and spinal cord following oral administration. ...Therefore, there is no clear knowledge regarding an understanding of the reported effects of selegiline on the progression o …
Selegiline is readily absorbed from the gastrointestinal tract and rapidly enters the brain and spinal cord following oral administra …
Selegiline ameliorated dyslipidemia and hepatic steatosis in high-fat diet mice.
Tian Z, Wang X, Han T, Sun C. Tian Z, et al. Int Immunopharmacol. 2023 Apr;117:109901. doi: 10.1016/j.intimp.2023.109901. Epub 2023 Feb 21. Int Immunopharmacol. 2023. PMID: 36822098
This study aimed to investigate the effects of a selective MAO-B inhibitor, selegiline, on dyslipidemia and hepatic steatosis in mice induced by a high-fat diet (HFD). ...Furthermore, selegiline dramatically reduced the total triglyceride (TG) and cholesterol (TC) l …
This study aimed to investigate the effects of a selective MAO-B inhibitor, selegiline, on dyslipidemia and hepatic steatosis in mice …
Selegiline for Alzheimer's disease.
Birks J, Flicker L. Birks J, et al. Cochrane Database Syst Rev. 2000;(2):CD000442. doi: 10.1002/14651858.CD000442. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2003;(1):CD000442. doi: 10.1002/14651858.CD000442. PMID: 10796544 Updated. Review.
All trials examined the cognitive effects of selegiline, and in addition, 12 trials examined the behavioural and mood effects. The results of 8 trials suggested some beneficial effect of selegiline in the treatment of cognitive deficits and in 3 trials in the treatm …
All trials examined the cognitive effects of selegiline, and in addition, 12 trials examined the behavioural and mood effects. The re …
Selegiline in the treatment of Parkinson's disease.
Heinonen EH, Rinne UK. Heinonen EH, et al. Acta Neurol Scand Suppl. 1989;126:103-11. doi: 10.1111/j.1600-0404.1989.tb01789.x. Acta Neurol Scand Suppl. 1989. PMID: 2515715 Review.
Improvement in parkinsonian disability and reduction of fluctuations in disability can be achieved by adding selegiline to the prevailing levodopa therapy. End-of-dose type fluctuations, in particular, react favourably to selegiline. ...Whether selegiline slo …
Improvement in parkinsonian disability and reduction of fluctuations in disability can be achieved by adding selegiline to the prevai …
3,067 results